Legal Representation
Attorney
Dyan M. House
USPTO Deadlines
Next Deadline
225 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20200804)
Due Date
August 04, 2026
Grace Period Ends
February 04, 2027
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
30 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Aug 4, 2025 | REM1 | E | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | Loading... |
| Aug 4, 2020 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| May 19, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| May 19, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Apr 29, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Apr 13, 2020 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Apr 13, 2020 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Apr 13, 2020 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Apr 13, 2020 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Apr 13, 2020 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Mar 30, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Mar 30, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Mar 26, 2020 | ERSI | I | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | Loading... |
| Sep 26, 2019 | GNS2 | O | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | Loading... |
| Sep 26, 2019 | GNSI | S | INQUIRY TO SUSPENSION E-MAILED | Loading... |
| Sep 26, 2019 | CNSI | R | SUSPENSION INQUIRY WRITTEN | Loading... |
| Sep 25, 2019 | RCCK | S | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | Loading... |
| Mar 19, 2019 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | Loading... |
| Mar 19, 2019 | GNSL | S | LETTER OF SUSPENSION E-MAILED | Loading... |
| Mar 19, 2019 | CNSL | R | SUSPENSION LETTER WRITTEN | Loading... |
| Mar 4, 2019 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Mar 4, 2019 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Mar 4, 2019 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Feb 27, 2019 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Aug 27, 2018 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Aug 27, 2018 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Aug 27, 2018 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Aug 13, 2018 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jul 2, 2018 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jun 30, 2018 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical products for ophthalmological use; pharmaceutical products for cardiovascular use; pharmaceutical preparations in the field of ophthalmology; pharmaceutical preparations in the field of cardiology; pharmaceuticals in the field of ophthalmology; pharmaceuticals in the field of cardiology; pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents
Class 010
Medical and surgical apparatus for use in general surgery; medical devices for the treatment of ophthalmological diseases and conditions; medical devices for the treatment of cardiovascular diseases and conditions; drug delivery systems
Class 042
Pharmaceutical research and development; pharmaceutical drug development services; consulting services in the field of pharmaceuticals and biotechnology research and development; conducting research and clinical trials relating to medical devices and pharmaceuticals in the field of ophthalmology; conducting research and clinical trials relating to medical devices and pharmaceuticals in the field of cardiology; development of pharmaceutical preparations and medicines; testing of pharmaceuticals
Classification
International Classes
005
010
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"THERAPEUTICS"